In colon cancer ERCC1 expression has been studied as a marker for sensitivity to combined therapies of 5-FU with other drugs, such as cisplatin, and different reports indicate that a high expression of ERCC1 is associated with poor prognosis [33]. Here, ERCC1 is linked to colonic neoplasm.